Company PhaseBio Pharmaceuticals, Inc.

Equities

PHAS.Q

US7172241090

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

End-of-day quote OTC Markets Other stock markets 06:00:00 2024-04-15 pm EDT			5-day change	1st Jan Change
0.000001 ^USD	0.00%		0.00%	0.00%

Apr. 19	First Amended Combined Liquidation Plan and Disclousre Statement Filed by PhaseBio Pharmaceuticals, Inc.	CI
Feb. 07	Fifth Motion for Exclusivity Period Extension Approved For PhaseBio Pharmaceuticals, Inc.	CI

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel therapies for cardiovascular diseases. Its lead product candidate, bentracimab (also known as PB2452), is a novel reversal agent for the antiplatelet drug ticagrelor. Ticagrelor is an antiplatelet therapy widely prescribed to reduce the rates of death, heart attack and stroke in patients with acute coronary syndrome (ACS), or who have previously experienced a heart attack. Ticagrelor binds to platelets to prevent them from forming blood clots that could restrict blood flow. The Company is also developing its preclinical product candidate, PB6440, an oral selective aldosterone synthase inhibitor for treatment-resistant hypertension. The Company is leveraging ELP biopolymer technology to evaluate additional preclinical and discovery-stage candidates. Its focus is on proteins and peptides that are scientifically or clinically validated.

Number of employees: 60

USD in Million	2020	Weight	2021	Weight	Delta
Novel Therapies 100.0 %	0	100.0 %	11	100.0 %	+3,284.69%

USD in Million	2020	Weight	2021	Weight	Delta
United States 100.0 %	0	100.0 %	11	100.0 %	+3,284.69%

Managers	Title	Age	Since
Jonathan Mow CEO	Chief Executive Officer	59	12-12-03
Lawrence Perkins DFI	Director of Finance/CFO	47	22-09-30
John Lee CTO	Chief Tech/Sci/R&D Officer	56	16-04-17
Susan Arnold CTO	Chief Tech/Sci/R&D Officer	49	10-09-30
Kristopher Hanson LAW	General Counsel	52	19-09-30

Members of the board	Title	Age	Since
Edmund Harrigan BRD	Director/Board Member	71	18-12-12
Jonathan Mow CEO	Chief Executive Officer	59	12-12-03
William Humphries BRD	Director/Board Member	57	21-09-13
Nancy Hutson BRD	Director/Board Member	74	18-03-04
Clay Thorp FOU	Founder	55	02-01-09
Richard van den Broek BRD	Director/Board Member	57	19-02-26
Alex Sapir BRD	Director/Board Member	57	20-02-11

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	49,888,083	49,767,625 ( 99.76 %)	29,967 ( 0.0601 %)	99.76 %

Name	Equities	%	Valuation
Hatteras Venture Partners 7.184 %	3,581,733	7.184 %	- $
Nancy Hutson 0.0833 %	41,510	0.0833 %	- $
Advice Capital A/S 0.0221 %	11,000	0.0221 %	- $
Edmund Harrigan 0.0196 %	9,750	0.0196 %	- $
Caroline Loewy 0.007521 %	3,750	0.007521 %	- $
Alex Sapir 0.007521 %	3,750	0.007521 %	- $
William Humphries 0.005090 %	2,538	0.005090 %	- $
Richard van den Broek 0.000000 %	0	0.000000 %	- $

PhaseBio Pharmaceuticals, Inc.

3500 South Dupont Highway Kent County

19901, Dover

+610 981 6500

http://www.phasebio.com

address PhaseBio Pharmaceuticals, Inc.(PHAS.Q)

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
PHASEBIO PHARMACEUTICALS, INC.	0.00%	49
VERTEX PHARMACEUTICALS INCORPORATED	-2.26%	103B
REGENERON PHARMACEUTICALS, INC.	+1.41%	95.71B
ARGENX SE	+0.79%	22.02B
BIONTECH SE	-17.84%	20.9B
GENMAB A/S	-11.11%	17.85B
WUXI APPTEC CO., LTD.	-42.83%	16.21B
BEIGENE, LTD.	-17.63%	15.52B
NEUROCRINE BIOSCIENCES, INC.	+4.55%	13.86B
SAREPTA THERAPEUTICS, INC.	+32.11%	12.04B

Bio Therapeutic Drugs